Latest Research And Development News

Opthea Limited has received a substantial A$10.8 million R&D tax incentive from the Australian government, reinforcing its commitment to advancing its novel drug candidate sozinibercept. This funding milestone underscores the company’s strategic focus on innovation and fiscal discipline.

4DMedical has secured $22.6 million through the exercise of deep in-the-money options, significantly strengthening its cash position to support the commercial rollout of its CT – VQ™ respiratory imaging technology.

Invex Therapeutics has ended negotiations on two neurological asset acquisitions following due diligence setbacks and shareholder disputes, while advancing R&D collaborations and managing financial stability.

Memphasys Limited has announced a pro-rata entitlement offer to raise approximately $1.12 million, issuing new shares at $0.003 each with free attaching options, aiming to fund the commercialisation of its Felix™ system and strengthen working capital.

Quantum Graphite Ltd reported a significant revenue jump alongside a $4.9 million net loss for FY2025, as it pushes forward with its Uley 2 graphite project backed by major infrastructure and funding initiatives.

Papyrus Australia has appointed Daniel Schmidt as CEO and secured a $250k government grant alongside a binding agreement to produce biodegradable mining products, marking a decisive shift from R&D to commercial operations.

CurveBeam AI Limited has secured A$6.5 million in new capital to fuel global growth of its HiRise™ weight-bearing CT scanner, deepen its partnership with orthopaedic giant Stryker, and advance a potential strategic deal in China.

CurveBeam AI has secured A$6.5 million through an institutional placement and completed a €10 million vendor financing facility to accelerate sales of its HiRise™ CT scanner. The company is also progressing a strategic partnership in China and advancing surgical robot validation.

HITIQ Ltd has raised $250,000 through a premium-priced placement and secured a $1.4 million RDTI loan facility to support its pivot towards consumer concussion management technology.

Firebird Metals has raised A$6 million through a placement led by top-tier institutions and directors, aiming to fast-track its manganese-rich cathode technology and expand R&D capabilities in Australia and China.

Bod Science Limited has reported a notable profit turnaround for FY2025, driven by medicinal cannabis sales growth, while navigating a complex Deed of Company Arrangement and a proposed backdoor listing with Biortica Agrimed Limited.

Arovella Therapeutics has received a $3.21 million R&D tax incentive refund, bolstering its financial position as it prepares to initiate first-in-human trials for its lead cell therapy, ALA-101.